Skip to main content

Table 3 Univariate and multivariate analysis (Cox regression models) assessing the relationship between baseline characteristics and time to treatment failure with AAP

From: Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

Covariate

Frequency

Univariate HR (95% CI) p-value1

Multivariate: no selection HR (95% CI) p-value2

Multivariate: backward selection HR (95% CI) p-value3

Age

 Unknown

0

N/A

N/A

 

 <  65

53

Reference

Reference

 

 65–75

188

1.011 (0.721–1.416) p-value = 0.9516

1.008 (0.711–1.429) p-value = 0.9651

 

 >  75

240

1.230 (0.886–1.708) p-value = 0.2154

1.148 (0.808–1.632) p-value = 0.4414

 

Comorbidities

 Unknown

0

N/A

N/A

 

 0

152

Reference

Reference

 

 1

143

1.253 (0.980–1.603) p-value = 0.0719

1.288 (0.994–1.669) p-value = 0.0556

 

 2

89

1.148 (0.865–1.525) p-value = 0.3392

1.140 (0.845–1.540) p-value = 0.3909

 

 ≥ 3

97

1.070 (0.805–1.422) p-value = 0.6413

0.937 (0.685–1.281) p-value = 0.6844

 

Alanine aminotransferase (ALT)

 Unknown

127

1.024 (0.803–1.304) p-value = 0.8498

0.969 (0.696–1.350) p-value = 0.8534

 

 ≤ 18

184

Reference

Reference

 

 >  18

170

0.825 (0.658–1.035) p-value = 0.0960

0.840 (0.657–1.073) p-value = 0.1623

 

Alkaline phosphatase (ALP)

 Unknown

124

1.111 (0.861–1.435) p-value = 0.4175

0.879 (0.624–1.239) p-value = 0.4627

0.964 (0.718–1.296) p-value = 0.8091

 ≤ 119

182

Reference

Reference

Reference

 >  119

175

1.816* (1.451–2.273) p-value = < 0.0001

1.491* (1.160 - 1.915) p-value = 0.0018

1.510* (1.189–1.919) p-value = 0.0007

Aspartate aminotransferase (AST)

 Unknown

248

1.294 (1.017–1.645) p-value = 0.0358

1.049 (0.758–1.452) p-value = 0.7709

 

 ≤ 24

118

Reference

Reference

 

 >  24

115

1.267 (0.953–1.684) p-value = 0.1034

1.183 (0.861–1.625) p-value = 0.3005

 

Hemoglobin

 Unknown

106

0.850 (0.661–1.095) p-value = 0.2085

1.039 (0.746–1.448) p-value = 0.8196

1.064 (0.785–1.443) p-value = 0.6890

 ≤ 12.5

192

Reference

Reference

Reference

 >  12.5

183

0.666* (0.534 - 0.831) p-value = 0.0003

0.783* (0.618–0.991) p-value = 0.0414

0.779* (0.621–0.977) p-value = 0.0309

LDH

 Unknown

297

1.294 (0.996–1.681) p-value = 0.0536

1.228 (0.867–1.740) p-value = 0.2467

 

 ≤ 277

92

Reference

Reference

 

 >  277

92

1.546* (1.124–2.125) p-value = 0.0074

1.278 (0.904–1.806) p-value = 0.2467

 

PSA

 Unknown

25

1.540 (0.997–2.379) p-value = 0.0518

1.674 (1.053–2.663) p-value = 0.0295

1.593 (1.012–2.506) p-value = 0.0442

 ≤ 56.2

228

Reference

Reference

Reference

 >  56.2

228

1.663* (1.359 - 2.034) p-value = <.0001

1.308* (1.046–1.634) p-value = 0.0183

1.412* (1.139–1.749) p-value = 0.0116

Gleason

 Unknown

46

1.275 (0.905–1.796) p-value = 0.1643

1.153 (0.798–1.667) p-value = 0.4483

 

 ≤ 7

204

Reference

Reference

 

 ≥ 8

231

1.266* (1.031–1.554) p-value = 0.0242

1.235 (0.997–1.529) p-value = 0.0532

 

ECOG

 Unknown

202

1.658 (1.277–2.153) p-value = 0.0001

1.479 (1.124–1.947) p-value = 0.0052

1.538 (1.182–2.002) p-value = 0.0014

 0

110

Reference

Reference

Reference

 1

134

1.641* (1.240 - 2.171) p.-value = 0.0005

1.378* (1.024–1.855) p-value = 0.0343

1.447* (1.086–1.927) p-value = 0.0116

 2/3/4

35

1.793* (1.179 - 2.727) p-value = 0.0063

1.558* (1.002–2.422) p-value = 0.0489

1.642* (1.074–2.510) p-value = 0.0219

Location of node metastases

 Unknown

315

0.913 (0.702–1.189) p-value =0.5002

0.880 (0.663–1.167) p-value = 0.3747

 

 Pelvic lymph node

80

Reference

Reference

 

 Iliac regional nodes

51

0.748 (0.512–1.094) p-value = 0.1346

0.763 (0.513–1.136) p-value = 0.1829

 

 Pelvic and iliac nodes

35

1.111 (0.734–1.681) p-value = 0.6187

1.110 (0.725–1.700) p-value = 0.6310

 

Location of metastases

 Unknown

16

1.034 (0.525–2.034) p-values = 0.9232

1.085 (0.537–2.191) p-value = 0.8203

 

 Bone and lymph node metastases

429

1.092 (0.744–1.604) p-values = 0.6523

0.884 (0.589–1.326) p-value = 0.5509

 

 Visceral

36

Reference

Reference

 
  1. *Denotes statistically significance
  2. 1Univariate HR contains the results from fitting a univariate Cox model with each covariate of interest
  3. 2Multivariate (no selection HR) contains the results from fitting a multivariate model with all covariates of interest included, no selection procedure was applied
  4. 3Multivariate (backward selection HR) contains the results from fitting a multivariate model in which covariates with a p-value < 0.10 in the univariate approach are included. A backward selection procedure was applied. Only the results of the final model are displayed. The covariates considered include age, number of comorbidities, ALP, ECOG, Gleason, hemoglobin, PSA. Please note that although age was not significant at the 10% level, it was included as it is considered clinically important. Only ALP, hemoglobin, PSA and ECOG were retained in the final model. The other variables were removed as their p-values were > 0.10
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us